• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Myriad Genetics Inc (NQ: MYGN )

    26.46 +0.23 (+0.88%)
    Streaming Delayed Price Updated: 2:41 PM EDT, Sep 27, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Myriad Genetics Inc

    < Previous 1 2 3 4 5 6 7 Next >
    Analyst Expectations For Myriad Genetics's Future
    Via Benzinga
    Myriad Genetics to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference
    MyRisk®, FirstGene®, Prequel®, and Foresight® studies among 10 datasets to be shared by Myriad 
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    G-III Apparel Posts Upbeat Results, Joins NIO, Yext, Shoe Carnival And Other Big Stocks Moving Higher On Thursday
    Via Benzinga
    Myriad Genetics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
    Via Benzinga
    Key Takeaways From Myriad Genetics Analyst Ratings
    Via Benzinga
    Myriad Genetics to Host Investor Event on October 9, 2024
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    Thermo Fisher Scientific Stock Sees RS Rating Jump To 81
    Thermo Fisher Scientific stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 77 to 81. 
    Via Investor's Business Daily
    MYGN Stock Earnings: Myriad Genetics Beats EPS, Beats Revenue for Q2 2024
    MYGN stock results show that Myriad Genetics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
    Via InvestorPlace
    Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    Myriad Genetics Advances International Reorganization and Completes Sale of EndoPredict Business to Eurobio Scientific
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    Avantor Stock Earns 84 RS Rating
    Avantor stock had its Relative Strength (RS) Rating upgraded from 78 to 84 Tuesday amid positive Q2 earnings results. 
    Via Investor's Business Daily
    Myriad Genetics to Release Second Quarter 2024 Financial Results on August 6, 2024
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk
    New Nationwide Survey Findings Show That More Than Half of Women Do Not Know That Breast Density Can Reveal Increased Risk of Breast Cancer 
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    Myriad Genetics Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    The 3 Best Gene Editing Stocks to Buy in July 2024
    Gene editing is revolutionizing medicine, creating substantial opportunities for some of the best gene editing stocks. 
    Via InvestorPlace
    Myriad Genetics Earns 2024 Great Place To Work® Certification™
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    Survey Suggests Increased Attention on Mental Health Warranted in the Run-Up to the Election
    New Findings from Myriad Genetics Reveal One-Third of Americans Say Election Season Affects Their Mental Health 
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests
    Myriad Genetics Inc. (NASDAQ: MYGN) is a leader in genetic testing and precision medicine. The company offers a wide variety of genetic tests including 
    Via MarketBeat
    Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries
    New sponsored testing program leverages Myriad’s MyChoice Tests for patients with high-grade serous ovarian cancer 
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    Myriad Genetics Launches New Universal Plus Panel for Foresight® Carrier Screen
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    Genomics Game-Changers: 3 Stocks Unlocking the Secrets of Life
    Genomics is the future of medicine, creating big opportunity for some of the top genomics stock picks to buy today. 
    Via InvestorPlace
    Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting
    Molecular Residual Disease (MRD) study and multiple RiskScore studies among seven new datasets to be shared by Myriad and Collaborators 
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    Louisiana-Pacific Posts Upbeat Results, Joins Cricut, Elanco Animal, American Public Education And Other Big Stocks Moving Higher On Wednesday
    Via Benzinga
    Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.